News, videos, social media and more about the recently released MINDACT phase III, prospective randomized trial results 

The primary analysis from the MINDACT clinical trial was presented by Martine Piccart, MD, PhD at the American Association for Cancer Research (AACR) annual meeting on Monday, April 18th providing MammaPrint 70-gene assay with the first and only Level 1A clinical utility evidence for chemotherapy benefit. Here is what the oncology community is saying about this data…

 

ARTICLE LINKS

 

VIDEO LINKS

 

YouTube


Dr. Martine Piccart MD, PhD discusses the MINDACT trial results at AACR 2016